董秘王哲宇突然卸任，振东制药“二代”董事长顶上

Core Viewpoint - Wang Zheyu, the Vice President and Board Secretary of Zhendong Pharmaceutical, submitted his resignation due to a job transfer, although he will continue to hold other positions within the company. His early departure raises questions about potential changes in company plans [1][5]. Group 1: Career Progression - Wang Zheyu's career trajectory shows a clear path from the pharmaceutical industry to capital investment and back to pharmaceuticals, indicating a strong understanding of both sectors [1]. - From 2012 to 2017, he gained experience in the pharmaceutical industry at Yabao Pharmaceutical, where he learned to analyze the industry and participate in project investments [2]. - He later became an Investment Director at Songshan Capital, focusing on identifying and managing investments in the pharmaceutical and consumer sectors [2]. - Between 2017 and 2022, he worked at Tianfeng Securities and then at Lujizhi Technology Group, where he transitioned from an investor to a company manager, successfully leading the company to the Hong Kong stock market [3]. Group 2: Role at Zhendong Pharmaceutical - In April 2022, Wang Zheyu returned to the pharmaceutical sector as the General Manager of the Strategy Department at Zhendong Pharmaceutical, overseeing legal affairs and strategic planning [3]. - By May 2023, he was promoted to Vice President and Board Secretary, taking on significant responsibilities as the company's spokesperson and compliance officer [4]. Group 3: Company Challenges and Developments - During Wang Zheyu's tenure as Board Secretary, Zhendong Pharmaceutical faced a significant arbitration case related to product quality issues, resulting in a total compensation payment of 500 million yuan to Langdi Pharmaceutical [6][7]. - The company also received a regulatory letter from the Shanxi Securities Regulatory Bureau regarding undisclosed fund occupation by the controlling shareholder, amounting to 51.3 million yuan [8][9]. - Despite these challenges, Zhendong Pharmaceutical's market value increased from 58.67 billion yuan in May 2023 to 60.73 billion yuan by January 2026 [10][11]. Group 4: Financial Performance - For the first three quarters of the previous year, Zhendong Pharmaceutical reported revenues of 2.215 billion yuan, a year-on-year decrease of 2.42%, and a net profit of 20.36 million yuan, down 49.25% [16]. - However, the company showed a strong performance in the third quarter, achieving revenues of 758 million yuan and a net profit of 124.33 million yuan, representing a year-on-year increase of 31.34% [16].